New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the...
Biomerica Inc. , a global leader in innovative medical diagnostics, proudly announces a landmark multi-year exclusive distribution agreement with one of th...
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candida...
GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), adv...
QIAGEN has announced the approval of its NeuMoDx human immunodeficiency virus type 1 (HIV-1) assay for use in Thailand. This approval completes the suite o...
Observation: ACROBiosystems' relentless commitment to innovation and strategic partnerships underscores its pivotal role in advancing organoid research and...
Incyte and China Medical System Holdings Limited are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...
GE HealthCare (Nasdaq: GEHC) announces the U.S. FDA 510(k) Clearance of IONIC Health’s revolutionary nCommand Lite technology, aimed at mitig...
Isansys Lifecare, led by the visionary Keith Errey, has gained recognition in the global healthcare technology market, particularly through its suc...
QIAGEN has announced a collaborative effort with the International Panel Physicians Association (IPPA) to bolster awareness of tuberculosis (TB) screening ...
Financial results of fiscal 2023 Net sales decrease organically by 1.6% to € 21.0 billion EBITDA pre down organically by 9.0% to € ...
The Change Healthcare Ransomware Payment Change Healthcare, a key player in the medical services sector owned by UnitedHealth Group, fell victim t...
MHTC has made significant strides in advancing agency-wide operational excellence which has been crucial to strengthening its foundation and positioning th...
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selato...
© 2024 Biopharma Boardroom. All Rights Reserved.
